双特异性抗体

TCR-JANUS 衔接蛋白实现双特异性靶向以克服 TCR-T 细胞治疗中的肿瘤异质性

TCR-JANUS engager proteins enable bispecific targeting to overcome tumor heterogeneity in TCR-T cell therapy.

αTrop2/αCD3 双特异性蛋白衔接器武装的 T 细胞（BATs）对鼻咽癌表现出强效抗肿瘤活性

αTrop2/αCD3 bispecific protein engager-armed T cells (BATs) exhibit potent antitumor activity against nasopharyngeal carcinoma.

胃食管癌治疗中有前景的新平台和靶点

Promising New Platforms and Targets in the Management of Gastroesophageal Cancers.

小细胞肺癌的新兴疗法与转化进展：克服耐药性

Emerging therapies and translational advances in small cell lung cancer: Overcoming resistance.

靶向 Glypican 3 的 CAR-T 细胞分泌靶向 TROP2 的双特异性 T 细胞衔接器对肺鳞状细胞癌表现出强效疗效

Glypican 3-targeted chimeric antigen receptor T cells secreting TROP2-directed bispecific T cell engagers exhibit potent efficacy against lung squamou

本研究表明，GPC3 CAR-T。

乳腺癌中新兴的靶向与多模式治疗策略：综合综述

Emerging Targeted and Multimodal Therapeutic Strategies in Breast Cancer: A Comprehensive Review.

胃癌中的抗体介导治疗：过去、现在与未来

Antibody-Mediated Therapy in Gastric Cancer: Past, Present, and Future.

经治胃癌患者的药物治疗：当前选择与未来进展

Pharmacotherapy for previously treated gastric cancer patients: current options and future developments.

生物标志物驱动的治疗有望在未来成为主流方法。

晚期前列腺癌中的肿瘤细胞表面靶向

Targeting the tumour cell surface in advanced prostate cancer.

过继性细胞治疗在小细胞肺癌中的进展

Advances in adoptive cell therapies in small cell lung cancer.